Tissue-engineered Skin Graft Repair of Autologous Scar Dermal Scaffolds

Launched by FIRST AFFILIATED HOSPITAL, SUN YAT-SEN UNIVERSITY · May 11, 2020

Keywords

ClinConnect Summary

This clinical trial is exploring a new way to treat hypertrophic scars, which are thick, raised scars that can form after an injury or surgery. These scars can cause discomfort and affect a person's quality of life. Currently, skin grafting is the best method for treating these scars, but it often comes with challenges like limited skin availability and a risk of the scars coming back. Researchers are testing a technique that combines skin cells and structures taken from the patient's own scar tissue to improve healing and reduce the chances of the scar returning.

To participate in this trial, you must have a hypertrophic scar that needs surgical repair, and the scar must be between 10 and 200 square centimeters in size. Participants will undergo surgery where the new treatment will be applied, and they can expect regular follow-ups to monitor their progress. This study aims to develop better treatment options for hypertrophic scars, potentially leading to improved outcomes for patients. If you or someone you know is considering participating, ensure you meet the eligibility criteria and are prepared for the follow-up process.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patient is diagnosed as hypertrophic scar and needs surgical repair; The scar size was 10cm2 to 200cm2, and the site was not limited; Patients with stable vital signs and tolerable operation indicated by routine examination; Patients in good mental state, can follow the doctor's advice, regular return; Those whom the researchers considered unsuitable for inclusion; Patients have participated in this study at any time in the past; Those whom the researchers considered unsuitable for inclusion; Patients have participated in this study at any time in the past.
• Exclusion Criteria:
• • Those who did not meet the inclusion criteria were found after the selected subjects; The follow-up time after inclusion was less than 2 times, and the objective efficacy could not be evaluated (but the adverse reactions could be evaluated); Subjects who violate protocol requirements.